^
    Back
    Association details:
    Biomarker:LY9 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug Class:T-lymphocyte cell therapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2020
    Title:

    Abstract 3250: CD229-targeted CAR T cell therapy for the treatment of B cell lymphoma

    Published date:
    08/15/2020
    Excerpt:
    Expression analysis of 12 B cell lymphoma cell lines including diffuse large B cell lymphoma (DLBCL)...revealed consistent expression of CD229 transcript...Coculture of CD229 CAR T cells with B cell lymphoma cell lines resulted in effective eradication of B cell lymphoma cells (two DLBC…at low effector-target ratios while control CAR T cells had no effect.
    DOI:
    10.1158/1538-7445.AM2020-3250